CEO & President of Protagonist Therapeutics. 38 years of executive, entrepreneural, and scientific experience spanning big pharma & biotechs, and loving it!
Fremont, Sunny California
Joined February 2010
- Tweets225
- Following86
- Followers165
- Likes396
From Local to Global; gratifying to see #MIMRYLO reaching to patients globally. Big Congrats to our partner @TakedaPharma. A huge motivator for team @ProtagonistTx to keep doing what it does best; inventing new medicine to address unmet needs globally. Cheers!
MIMRYLO™ (rusfertide) has been approved in the United Arab Emirates for adults with Polycythemia Vera (PV).
The Protagonist team is very pleased to see MIMRYLO reaching more patients around the world.
#PolycythemiaVera #RareDisease #BloodCancer
tinyurl.com/bderkhee
An easy read on a complex topic of oral peptides (the holy grail) by @david_wainer of @WSJ. At @ProtagonistTx we’re committed to this endeavor.
The real opportunity is pill-form peptides that could hit big pharma’s most profitable franchises. on.wsj.com/4he7EVl
From local to global; very pleased to see ICOTYDE expanding its outreach. Best news for psoriasis patients who prefer a safe and effective needle-free treatment with the convenience of a once daily oral pill.
This week, the European Commission approved ICOTYDE™ (icotrokinra) for adults and adolescents with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
Following approvals in the U.S. and China, European approval represents another important step in the global expansion of ICOTYDE — and further demonstrates the potential of targeted oral peptides to become an important new therapeutic option for patients worldwide.
ema.europa.eu/en/medicines/h…
#ICOTYDE #PeptideTherapeutics #PTGX
Great example of a win-win partnership between a Biotech @ProtagonistTx and a Pharma Company @Takeda Pharmaceuticals.
Takeda’s MIMRYLO approval unlocks $275m for Protagonist and a $1bn-plus PV bet business-news-today.com/take… $TAK $PTGX #Takeda #ProtagonistTherapeutics #MIMRYLO #Rusfertide #PolycythemiaVera #Hematology #FDA
Dinesh V. Patel, PhD retweeted
Takeda’s MIMRYLO approval unlocks $275m for Protagonist and a $1bn-plus PV bet business-news-today.com/take… $TAK $PTGX #Takeda #ProtagonistTherapeutics #MIMRYLO #Rusfertide #PolycythemiaVera #Hematology #FDA
I will never get tired of uttering - 'first-in-class'. Looking forward to real patients benefiting from MIMRYLO.
A new chapter in #PolycythemiaVera treatment begins.
The FDA has approved MIMRYLO™ (rusfertide), the first hepcidin mimetic for erythrocytosis in adults with PV.
What patients should know:
pvreporter.com/fda-approves-…
#BloodCancerAwarenessMonth #Mimrylo
And indeed, it does take a village, a busy village. Cheers!
The FDA approval of MIMRYLO™ (rusfertide) marks the culmination of more than a decade of work at Protagonist.
Members of our team reflect on the journey and the patients, investigators, partners, and colleagues who helped make it possible.
#PTGX #FDAApproval #PV
Great to see that #ICOTYDE is spreading its wings. Let the journey continue and touch and better as many lives as possible. Cheers!
China’s drug regulator has approved #ICOTYDE for moderate-to-severe plaque psoriasis.
ICOTYDE continues to demonstrate the power of our peptide discovery platform and long-term collaboration with Johnson & Johnson. With approvals now in the U.S. and China, we look forward to the European Commission’s decision and the potential to bring this differentiated oral therapy to more patients globally.
finance.yahoo.com/healthcare…
#Psoriasis #IL23 #OralPeptides
It was great to join @SchwabNetwork last Friday. Thanks to the Schwab team for having me, and to the entire @ProtagonistTx team whose non-stop hard work continues to move our company forward and advance new medicines for patients.
On Friday, @ProtagonistCEO Dinesh Patel joined @SchwabNetwork #NextGenInvesting live to discuss peptides, obesity, and biopharma disruption.
Watch it here: schwabnetwork.com/video/prot…
#schwabnetwork
Very gratifying, humbling, satisfying, all at the same time. Thanks and Congrats to all involved for this wonderful recognition.
Today, ICOTYDE™ was nominated for the 2026 #PrixGalien USA Award for Best Pharmaceutical Product.
This recognition by @GalienFdn highlights the scientific innovation behind the first and only FDA-approved targeted oral peptide designed to block the IL-23 receptor, bringing a novel plaque psoriasis treatment approach that combines the established efficacy and safety of IL-23 pathway blockade with the convenience of a once-daily oral pill.
We’re gratified to see an innovation that began at Protagonist being recognized among this year's nominees and congratulate our colleagues at Johnson & Johnson, the Protagonist team, clinical investigators, and the patients who helped make this possible.
#PeptideTherapeutics #DrugDiscovery #Innovation
prnewswire.com/news-releases…
UNBELIEVABLE! ispot.tv/ad/gvER/icotyde-unb…
11,000 patients initiated. 18,000+ prescriptions written. 6,000 unique prescribers. More than 50% commercial coverage within 90 days. These are some of the metrics behind the early momentum of #ICOTYDE, as shared in Johnson & Johnson’s Q2 earnings call this morning.
We are encouraged by the strong early momentum and excited about what lies ahead.
Hear more from Johnson & Johnson’s Q2 earnings call: tinyurl.com/5hdypadm
#PTGX #PeptideTherapeutics
And the journey of great science in hematology to serve humankind continues. Well done team @ProtagonistTx
Rusfertide, currently under a priority NDA review at FDA, is the outcome of a research program initiated at @ProtagonistTx in 2012. By opting-out of further co-development and co-commercialization, we place the company in an even stronger financial position while benefiting patients, our shareholders, and @TakedaPharma. Eagerly awaiting the potential approval in third quarter. Cheers!
Protagonist has exercised its right to opt out of the 50:50 U.S. profit and loss sharing arrangement under our worldwide license and collaboration agreement with Takeda for rusfertide, an investigational first-in-class hepcidin mimetic peptide. Rusfertide is now under U.S. Food and Drug Administration (FDA) Priority Review for the treatment of adults with polycythemia vera (PV).
Read more: accessnewswire.com/newsroom/…
Slow and steady does it. Humble beginnings from 2008 to now, but we are just not done yet. Repeat performance is the real charm. Cheers!
What a week for all of us at Protagonist! After celebrating the FDA Approval of ICOTYDE, we are thrilled to be recognized on the Nasdaq Tower in Times Square as a Fast 500 company. Ranking among the fastest-growing innovative companies in North America is a powerful validation of our innovation platform. To our customers, partners, and every member of the Protagonist family: This moment belongs to you. We’re just getting started. Looking forward to what's yet to come.
#PTGX #NASDAQ #BayAreaFast500 #Biotech #Innovation
Dinesh V. Patel, PhD retweeted
Congrats dad (@ProtagonistCEO)!
I'm *so* proud of what you and the @ProtagonistTx team have achieved. 13yrs end-to-end from R&D to full FDA approval for a new drug. It's inspiring.
Proud moment for Protagonist Therapeutics: today’s FDA approval of ICOTYDE marks 13 years of scientific dedication and operational excellence.
A testament to our peptide platform and collaboration with Johnson & Johnson. Grateful to all who made this possible.
Today the FDA approved ICOTYDE™ (icotrokinra), the first targeted oral peptide option for first-line systemic treatment of plaque psoriasis.
This milestone reflects the power of our science and platform. Thank you to the PTGX team, Johnson & Johnson, investigators and patients who made it possible.
Read more: bit.ly/4sckfLP
The FDA’s decision to grant Priority Review for rusfertide marks an important step in our decade-plus long and ongoing journey. Big Congrats and sincere thanks to the @ProtagonistTx team for your persistence, scientific rigor, and commitment. We are pleased to be working with Takeda on this potential first-in-class therapy for patients with polycythemia vera.
Today, Protagonist and Takeda announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for rusfertide, an investigational, first-in-class hepcidin mimetic peptide therapeutic for the treatment of adults with polycythemia vera (PV).
Read more details in our latest press release: feeds.issuerdirect.com/news-…
Protagonist is off to a strong start in 2026.
Together with Takeda, we’ve submitted an NDA to the FDA for rusfertide, a first-in-class investigational hepcidin mimetic for PV. Grateful to the patients, investigators, and teams who made this possible.
Looking forward to JPM and sharing more updates ahead!
Takeda and Protagonist Therapeutics have announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV).
Read more in our latest press release: bit.ly/4sqgV03